Virtu Financial’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Virtu Financial’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,949	Closed	-$424K	–	2357
2023 Q1	$424K	Buy	+3,949	New	+$455K	0.05%	401
2022 Q4	–	Sell	-4,956	Closed	-$292K	–	2402
2022 Q3	$292K	Buy	+4,956	New	+$227K	0.03%	661
2022 Q2	–	Sell	-5,311	Closed	-$201K	–	2289
2022 Q1	$201K	Buy	+5,311	New	+$210K	0.01%	779

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Virtu Financial's RXDX Position: Q2 2023 in Review

Virtu Financial sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,949 shares — an estimated $424K sold.

Virtu Financial first reported a position in RXDX in Q1 2022 and held it in 3 quarters. The position peaked at $424K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Virtu Financial reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Virtu Financial sold 3,949 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $424K.
Virtu Financial first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Virtu Financial's Prometheus Biosciences, Inc. Common Stock position peaked at $424K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Virtu Financial's 13F filing for Q2 2023, filed 27 Jul 2023.